4 results
To assess the safety, tolerability and the effects of treatment on ocular outcomes following a single intravitreal administration of ESBA1008 compared to Lucentis in patients with exudative AMD
Primary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg with respect to the change in best-corrected visual acuity (BCVA) from Baseline to Week 48Secondary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg…
• The primary objective is to demonstrate non-inferiority of the detection rate of clinically significant prostate cancer (defined as GG >= 2) in targeted biopsies based on PCaVision imaging (PCaVision pathway) in comparison with the…
Primary:To demonstrate the non-inferior antiviral activity of CAB LA + RPV LA every two months compared to a BIK single tablet regimen administered once daily over 12 months in suppressed HIV-1 infected antiretroviral therapy (ART)-experienced…